For many medical device startups, the first major technical milestone is proving that the concept works. While a functional prototype proves an idea is possible, it reveals little about whether the device can be built the same way, at volume, under a compliant quality system, by people who aren’t the engineers who built the first one.
That gap between “it works” and “it’s ready to manufacture and sell” is a common source of late-stage surprises for early-stage teams. Luckily, even novel innovations go through a set of predictable pressure points. Teams that get ahead of the issues below save on months of rework and preserve critical milestones.
#1 Designing for Function Instead of Manufacturability
Early engineering decisions are made to solve a technical problem, not to support a repeatable build process. That trade-off is often invisible until someone tries to produce the device outside a lab bench.
Common patterns that surface later as expensive problems:
- Tight tolerances chosen for performance, not for what a production line can hold consistently
- Custom or single-source components with no qualified second supplier
- Assembly steps that depend on a specific technician’s hands, not a documented, repeatable process
- Materials selected for prototype availability or cost without fully considering biocompatibility, processing, sterilization compatibility, regulatory requirements, or long-term supply.
None of these are wrong choices during early R&D, but they become expensive when nobody revisits them before scaling. The manufacturing partner then has to reverse-engineer manufacturability into a design that wasn’t built for it. Bringing design and development expertise in earlier, even at the concept stage, means your team can make trade-offs with production in mind from the start rather than discovering them during design transfer.
#2 Underestimating How Long the Quality System Actually Takes
Lean product teams often treat quality system implementation as a task to complete once the design is finalized. In practice, a compliant quality system should develop alongside the product, capturing design and development activities, risk management, and required records as the work occurs.
Teams that wait often confront difficult questions later, such as:
- Do our existing records adequately demonstrate that required design and development controls were followed?
- Are product and process risks appropriately documented and traceable to design decisions?
- How long will it take to identify and close gaps before an audit, submission, design transfer, or commercial launch?
Addressing quality-system requirements retroactively is generally slower, more difficult, and more disruptive than building them into the development process from the beginning.
Related Reading: FDA QMSR Explained: What Early-Stage Medical Device Companies Need to Know
#3 Treating the Prototype as a Finished Product
A functional prototype and a commercial-ready product solve different problems. A prototype has to work once, in a controlled setting, in front of people who already understand its quirks. A commercial product has to work consistently and safely, at volume, in the hands of people encountering it for the first time.
The gap between the two usually includes:
- Design for manufacturing (DfM) changes that were never made because the prototype “worked fine”
- Process validation and qualification activities that have to demonstrate the manufacturing method itself is repeatable, not just that one unit came out right
- Test and inspection methods built for a lab bench, not a production floor
- Packaging, sterilization, and shelf-life considerations that rarely come up until someone asks about them directly
Related Reading: From Lab Prototype to Commercial-Ready: Minding the Commercialization Gap
#4 Ignoring Supply Chain Risk Until It Becomes Urgent
Sourcing decisions made for convenience during prototyping (e.g., a component from a catalog or a supplier a founder already knew) often carry over into production. That’s fine until volume increases, a supplier has a quality issue, or a component becomes hard to source. At this stage, many startups discover there was never a backup plan. Early teams may simply lack the bandwidth or cross-functional expertise to plan beyond immediate technical milestones.
A few questions worth answering early rather than during a shortage:
- Which critical components have a qualified second source, and which don’t?
- What happens to the schedule if a supplier has a delay or quality issue?
- Are sourcing decisions being made with total cost and risk in mind, or just unit price?
Supply chain risk is easiest to manage when it’s considered at every stage of development, rather than addressed after a disruption.
#5 Not Prioritizing Human Factors and Usability Engineering
Usability engineering is frequently treated as a regulatory checkbox to be satisfied near the end of development, rather than as input to the design itself. Late-discovered errors often require design changes and rework, not just updated instructions for use.
Building usability studies into the design process (rather than validating a finished design after the fact) tends to surface problems while they’re still cheap to fix. It also creates a traceable record connecting user needs, use-related risks, evaluations, and resulting design decisions.
Takeaway: Consider Manufacturability in Early Design Stages to Preserve Time-to-Market
The fix isn’t more work upfront. It’s the right work up front: involving manufacturing, quality, and regulatory expertise while the design is still flexible, instead of after it’s fixed. Startups that build this way don’t just get to market. They reduce the risk of paying twice for the same decision.
Ascential works with early-stage medical device teams to close these gaps before they become expensive, bringing product design and launch expertise, quality systems knowledge, and manufacturing scale-up experience into the process at every stage. Let’s talk through where your product stands today.
Get Your 15-Minute Consultation